Tc 99m votumumab

Drug Profile

Tc 99m votumumab

Alternative Names: HumaSPECT; Votumumab

Latest Information Update: 18 May 2007

Price : $50

At a glance

  • Originator Intracel Corporation
  • Class Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Market Withdrawal Colorectal cancer

Most Recent Events

  • 18 May 2007 Discontinued - Phase-III for Colorectal cancer diagnosis in USA (IV)
  • 12 Sep 2003 KS Biomedix Holdings has been acquired by Xenova Group
  • 26 Feb 2003 Launched for Colorectal cancer diagnosis in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top